Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience.

Gehl, H; Urhahn, R; Bohndorf, Klaus; Klever, P.; Hauptmann, S.; Lodemann, Klaus‐Peter; Matern, Siegfried; Schumpèlick, V.; Günther, Rolf W.

doi:10.1148/radiology.186.3.8430190

Cited by 69 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Enhancement of the pancreas started 3 min after administration and reached its maximum of 98% (at 10 µmol kg −1 bw) after 1.5 h. The tumour-parenchyma contrast of pancreatic cancer was increased by 209% [40]. Mangafodipir at a dosage of 5 µmol kg −1 still increased the tumour-pancreas contrast by up to 70% on T1w FS-TSE and by 80% on T1w GRE images 20 min post-contrast [41], which improves the detection of pancreatic cancer and liver metastases [42].…”

Section: Mangafodipir Trisodiummentioning

confidence: 99%

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

Hepatobiliary contrast agents with uptake into hepatocytes followed by variable biliary excretion represent a unique class of cell-specific MR contrast agents. Two hepatobiliary contrast agents, mangafodipir trisodium and gadobenate dimeglumine, are already clinically approved. A third hepatobiliary contrast agent, Gd-EOB-DTPA, is under consideration. The purpose of this review is to provide an overview on the properties, clinical development and application of these three hepatobiliary contrast agents. Bolus injectable paramagnetic hepatobiliary contrast agents combine established features of extracellular agents with the advantages of hepatocyte specificity. The detection and characterisation of focal liver disease appears to be improved compared to unenhanced MRI, MRI with unspecific contrast agents and contrast-enhanced CT. To decrease the total time spent by a patient in the MR scanner, it is advisable to administer the agent immediately after acquisition of unenhanced T1-w MRI. After infusion or bolus injection (with dynamic FS-T1-w 2D or 3D GRE) of the contrast agent, moderately and heavily T2w images are acquired. Post-contrast T1-w MRI is started upon completion of T2-w MRI for mangafodipir trisodium and Gd-EOB-DTPA as early as 20 min following injection, while gadobenate dimeglumine scans are obtained >60 min following injection. Post-contrast acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by MSCT combined with an unparalleled improvement in tumour-liver contrast. The individual decision that hepatobiliary contrast agent one uses is partly based on personal preferences. No comparative studies have been conducted comparing the advantages or disadvantages of all three agents directly against each other.

show abstract

Section: Mangafodipir Trisodiummentioning

confidence: 99%

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

show abstract

“…After intravenous administration, mangafodipir is taken up into the pancreas parenchyma, which leads to a prolonged and significant enhancement of the pancreas on T1-w images [36], whereas there is no or minimal contrast material uptake into adenocarcinomas [37]. This leads to an increased conspicuity of pancreatic cancer on enhanced T1-w GRE images [38], which improves tumor detection (Fig.…”

Section: Detection Of Adenocarcinomamentioning

confidence: 99%

Pancreatic adenocarcinoma

et al. 2006

View full text Add to dashboard Cite

Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head of the pancreas in 60-70% of cases. By the time of diagnosis, at least 80% of tumors are unresectable. Helical computed tomography (CT) is very effective in detecting and staging adenocarcinoma, with a sensitivity of up to 90% for detection and an accuracy of 80-90% for staging, but it has limitations in detecting small cancers. Moreover, it is not very accurate for determining nonresectability because small liver metastases, peritoneal carcinomatosis, and subtle signs of vascular infiltration may be missed. Multidetector-row CT (MDCT) has brought substantial improvements with its inherent ability to visualize vascular involvement in three dimensions. MDCT has been found to be at least equivalent to contrast-enhanced magnetic resonance imaging (MRI) for detecting adenocarcinoma. MRI can be used as a problem-solving tool in equivocal CT: MRI may help rule out pitfalls, such as inflammatory pseudotumor, focal lipomatosis, abscess, or cystic tumors. Mangafodipir-enhanced MRI reveals a very high tumor-pancreas contrast, which helps in diagnosing small cancers. Endosonography is, if available, also a very accurate tool for detecting small cancers, with a sensitivity of up to 98%. It is the technique of choice for image-guided biopsy if a histologic diagnosis is required for further therapy.

show abstract

“…These tumors exhibit low signal intensity on T1-and T2-weighted MR images, and show less enhancement than the parenchyma of the pancreas on gadolinium-enhanced GRE MR images [13]. Mangafodipir is an organ-specific MR contrast agent that accumulates predominantly in the liver and the parenchyma of the pancreas [14]. Contrast enhancement of pancreatic parenchyma may improve delineation of focal pancreatic masses, which do not show uptake of the contrast agent; however, mangafodipir does not aid in the differential diagnosis for the presence of cancer or focal pancreatitis.…”

Section: Discussionmentioning

confidence: 99%